AstraZeneca well positioned to join cancer immunotherapy race: Reuters


AstraZeneca (AZN +0.5%) may be a step behind Roche (RHHBY.OB +0.9%), Bristol-Myers (BMY +0.3%), and Merck (MRK -1.3%) when it comes to developing immunotherapies to treat cancer, but "the field is still very open for combinations and [AZN is] very much in the race," the company's head of biologics Bahija Jallal says.

The "breadth" of AZN's pipeline and the "pace of cancer drug development" may help AZN catch up to industry leaders quickly, Reuters notes.

One promising candidate is the PD-L1 blocker MEDI4376 which may prove most effective when paired with other drugs such as tremelimumab which "works in a similar way to BMY's Yervoy."

Late last month, Roche reported positive results for its PD-LI drug MPDL3280A in NSCLC.

From other sites
Comments (1)
  • 5967241
    , contributor
    Comments (107) | Send Message
     
    AZN is always a step behind other. Take the example of one of their recent purchases--> OMTH which doesn't have an approved drug, patent or a pipeline. Half a billion thrown into garbage even after knowing that the competitors are already way ahead of them.
    14 Oct 2013, 02:45 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs